

Catalog # 10-4120 THZ1

CAS# 1604810-83-4

(E)-N-(3-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)-4-(4-(dimethylamino)but-2-enamido)benzamide Lot # FBS2189

THZ1 is an irreversible, covalent inhibitor (dual ATP-site and allosteric covalent binding) of CDK7 (IC₅₀ = 15.6nM @ 20min and 3.2nM @ 180 min).¹ It displayed broad based antiproliferative activity with IC₅₀'s of less than 200nM against 53% of the 1000 cancer cell lines it was tested against. THZ1 disrupts transcription of several proteins including RUNX1, TAL1, and GATA3. It suppresses oncogenic transcription of MYCN-driven cancers.² THZ1 decreases STAT3 chromatin binding and expression of target genes such as MYC, PIM1, and others in peripheral T-Cell lymphoma cells with the Y640F STAT3 mutation.³ Addition of THZ1 to targeted cancer therapy increases cell death and hinders the development of drug-resistant cell populations in cellular and *in vitro* cancer models.⁴

- 1) Kwiatkowski et al. (2014), Targeting transcription regulation in cancer with a covalent CDK7 inhibitor; Nature, 511
- 2) Chipumuro et al. (2014), CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription of MYCN-driven cancers; Cell , **159** 1126
- 3) Cayrol et al. (2017), THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors; Nature Commun.,**8** 14290
- 4) Rusan et al. (2018), Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression; Cancer Discov., **8** 59

PHYSICAL DATA

Molecular Weight: 566.05

Molecular Formula: $C_{31}H_{28}CIN_7O_2$ Purity: >97% by HPLC NMR: (Conforms)

Solubility: DMSO (>25 mg/ml)

Physical Description: Tan solid

Storage and Stability: Store as supplied at -20°C for up to 1 year from the date of purchase. Solutions in

DMSO may be stored at -20°C for up to 3 months.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.